Trinity Biotech PLC

TRIB Healthcare Medical Devices

Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024.

Revenue
+43.3%
EPS
+52.1%
Free cash flow
+75.2%
Total debt
+29.9%

Quarter to March 2026, against a year earlier

6.07 0.17 +2.88%
Market cap
$3.8M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
4/9
Altman Z
−2.78
Beneish M
−4.29
Dividend safety
n/a
Older periods Jun '25 Sep '25 Dec '25 Mar '26
ROE

+8 more TTM periods

92.42% 90.93% 69.76% 55.26%
Piotroski F-Score
1 2 4 4
ROA
(37.61%) (36.64%) (35.86%) (32.70%)
ROIC
(25.55%) (23.73%) (16.99%) (12.61%)
Return on Tangible Assets
(630.54%) (732.37%) 37.37% 30.75%
Average Days of Receivables
80.47 108.88 95.70 81.54
Free Cash Flow per Share
(26.07) (18.00) (22.76) (6.78)
Free Cash Flow
(16.17) (11.18) (14.08) (4.28)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026